Literature DB >> 24732285

Complete endoscopic mucosal resection is effective and durable treatment for Barrett's-associated neoplasia.

Vani J A Konda1, Mariano Gonzalez Haba Ruiz1, Ann Koons1, John Hart2, Shu-Yuan Xiao2, Uzma D Siddiqui1, Mark K Ferguson3, Mitchell Posner3, Marco G Patti3, Irving Waxman4.   

Abstract

BACKGROUND & AIMS: Barrett's esophagus (BE) with high-grade dysplasia (HGD) or intramucosal carcinoma (IMC) is treated by complete eradication of areas of BE by endoscopic mucosal resection (EMR). By using this approach, histologic analysis also can be performed. We investigated the effectiveness, safety, and durability of this approach, as well as its use in diagnosis after a single referral.
METHODS: We collected data from 107 patients who were referred to the Center for Endoscopic Research and Therapeutics at the University of Chicago for BE (mean length, 3.6 cm) with suspected HGD or IMC, from August 2003 through December 2012. All patients underwent EMR and were followed up through January 2014 (mean follow-up time, 40.6 mo). The primary outcome was treatment efficacy (complete eradication of BE and associated neoplasia); secondary outcomes included safety, durability, and accuracy of diagnosis.
RESULTS: BE was eradicated completely by EMR in 80.4% (86 of 107) of patients based on intention-to-treat analysis, and in 98.8% (79 of 80) of patients based on per-protocol analysis. The diagnosis was changed for 25% of patients after EMR, including 4 cases that initially were diagnosed as HGD by biopsy analysis and subsequently were found to have evidence of submucosal invasion when EMR specimens were assessed. Strictures and symptomatic dysphagia developed in 41.1% and 37.3% of patients, respectively, with an average of 2.3 dilations required. Perforations occurred in 2 patients after EMR and in 1 patient after dilation. HGD and IMC recurred in 1 patient each; both were treated successfully with EMR. Based on pathology analysis of the most recently collected specimens, 71.6% of patients (53 of 74) were in complete remission from intestinal metaplasia and 100% were in complete remission from HGD (74 of 74) or cancer (74 of 74).
CONCLUSIONS: For patients with BE with HGD or neoplasia, complete EMR is an effective and durable treatment and is a relatively safe technique. Specimens collected by EMR also can be analyzed histologically to aid in diagnosis. The common complication of EMR is esophageal stricture, which can be addressed with endoscopic dilation.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Endoscopy; Endotherapy; Esophageal Cancer

Mesh:

Year:  2014        PMID: 24732285     DOI: 10.1016/j.cgh.2014.04.010

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  15 in total

Review 1.  Multiband mucosectomy for advanced dysplastic lesions in the upper digestive tract.

Authors:  Jesús Espinel; Eugenia Pinedo; Vanesa Ojeda; Maria Guerra Del Rio
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

Review 2.  Endoscopic options for early stage esophageal cancer.

Authors:  Pari M Shah; Hans Gerdes
Journal:  J Gastrointest Oncol       Date:  2015-02

Review 3.  Performance measures for upper gastrointestinal endoscopy: A European Society of Gastrointestinal Endoscopy quality improvement initiative.

Authors:  Raf Bisschops; Miguel Areia; Emmanuel Coron; Daniela Dobru; Bernd Kaskas; Roman Kuvaev; Oliver Pech; Krish Ragunath; Bas Weusten; Pietro Familiari; Dirk Domagk; Roland Valori; Michal F Kaminski; Cristiano Spada; Michael Bretthauer; Cathy Bennett; Carlo Senore; Mário Dinis-Ribeiro; Matthew D Rutter
Journal:  United European Gastroenterol J       Date:  2016-08-21       Impact factor: 4.623

Review 4.  Post-ablation surveillance in Barrett's esophagus: A review of the literature.

Authors:  Matthew W Stier; Vani J Konda; John Hart; Irving Waxman
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

5.  Endoscopic Mucosal Resection as the Primary Treatment for Barrett Esophagus With Dysplasia.

Authors:  Prateek Sharma
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-10

Review 6.  Risk of recurrence of Barrett's esophagus after successful endoscopic therapy.

Authors:  Rajesh Krishnamoorthi; Siddharth Singh; Karthik Ragunathan; David A Katzka; Kenneth K Wang; Prasad G Iyer
Journal:  Gastrointest Endosc       Date:  2016-02-20       Impact factor: 9.427

Review 7.  Ablation Therapy for Barrett's Esophagus: New Rules for Changing Times.

Authors:  Nour Hamade; Prateek Sharma
Journal:  Curr Gastroenterol Rep       Date:  2017-08-17

Review 8.  Pathological assessment of endoscopic resections of the gastrointestinal tract: a comprehensive clinicopathologic review.

Authors:  M Priyanthi Kumarasinghe; Michael J Bourke; Ian Brown; Peter V Draganov; Duncan McLeod; Catherine Streutker; Spiro Raftopoulos; Tetsuo Ushiku; Gregory Y Lauwers
Journal:  Mod Pathol       Date:  2020-01-06       Impact factor: 7.842

9.  Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma: a Canadian experience.

Authors:  Denise Tami Yamashita; Chao Li; Drew Bethune; Harry Henteleff; James Ellsmere
Journal:  Can J Surg       Date:  2017-04       Impact factor: 2.089

Review 10.  Advances in the management of Barrett's esophagus and early esophageal adenocarcinoma.

Authors:  Ajaypal Singh; Amitabh Chak
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.